Drugs / IMU-935
last change May 2023 re-read 3 minutes ago

IMU-935

Developed for
prostate carcinoma
Investigated by
Immunic AG

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05124795 Dec 2021 → May 2023 prostate carcinoma Immunic AG Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IMU-935 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05124795 ↗